Alliance Global Partners analyst James Molloy initiated coverage of vTv Therapeutics (VTVT) with a Buy rating and $35 price target vTv is a clinical-stage pharmaceutical company focused on developing treatment options for metabolic and inflammatory diseases, primarily targeting type 1 diabetes, the analyst tells investors in a research note. The firm says cadisegliatin’s mechanism of action allows for liver function restoration.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTVT:
Questions or Comments about the article? Write to editor@tipranks.com